The year in non-st-segment elevation acute coronary syndrome

Journal of the American College of Cardiology

Volumn 56, Issue 25, 2010, Pages 2126-2138

  Giugliano, Robert P ^a   Braunwald, Eugene ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; BIOLOGICAL MARKER; BLOOD CLOTTING FACTOR 10A INHIBITOR; BLOOD CLOTTING INHIBITOR; C REACTIVE PROTEIN; CLOPIDOGREL; DZ 697 B; ENOXAPARIN; FIBRINOGEN RECEPTOR ANTAGONIST; FONDAPARINUX; HEPARIN; HIRULOG; LOW MOLECULAR WEIGHT HEPARIN; M 118; OMEPRAZOLE; OTAMIXABAN; PLACEBO; PRASUGREL; PROTAMINE; RANOLAZINE; RB 006; RB 007; RECOMBINANT HUMAN ALBUMIN INFESTIN 4; RIVAROXABAN; THIENOPYRIDINE DERIVATIVE; TICAGRELOR; TROPONIN I; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; ANTICOAGULANT THERAPY; BLEEDING; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CORONARY ARTERY BYPASS GRAFT; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC VALUE; DIET; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; EXERCISE; GASTROINTESTINAL HEMORRHAGE; HEART CATHETERIZATION; HEART FUNCTION; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART REHABILITATION; HUMAN; LIPID ANALYSIS; LOADING DRUG DOSE; LOW DRUG DOSE; MONOTHERAPY; NON ST SEGMENT ELEVATION ACUTE CORONARY SYNDROME; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; PATHOPHYSIOLOGY; PERCUTANEOUS CORONARY INTERVENTION; PHARMACODYNAMICS; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; REVIEW; RISK FACTOR; SMOKING CESSATION; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; THROMBOCYTE AGGREGATION; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME; UNSTABLE ANGINA PECTORIS;

ACUTE CORONARY SYNDROME; ANGIOPLASTY, BALLOON, CORONARY; ANTICOAGULANTS; BIOLOGICAL MARKERS; CARDIAC IMAGING TECHNIQUES; HEMORRHAGE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; PLATELET AGGREGATION INHIBITORS; QUALITY OF HEALTH CARE; RISK FACTORS;

EID: 78650051954     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2010.09.016     Document Type: Review

References (142)

1. K.A. Eagle, G.S. Ginsburg, and K. Musunuru Identifying patients at high risk of a cardiovascular event in the near future: current status and future directions: report of a national heart, lung, and blood institute working group Circulation 121 2010 1447 1454
2. J. Sanz, P.R. Moreno, and V. Fuster The year in atherothrombosis J Am Coll Cardiol 55 2010 1487 1498
3. K. Wolf, A. Schneider, and S. Breitner Air temperature and the occurrence of myocardial infarction in Augsburg, Germany Circulation 120 2009 735 742
4. M.L. Bell, R.D. Peng, F. Dominici, and J.M. Samet Emergency hospital admissions for cardiovascular diseases and ambient levels of carbon monoxide: results for 126 United States urban counties, 19992005 Circulation 120 2009 949 955
5. C.A. Pope III, R.T. Burnett, and D. Krewski Cardiovascular mortality and exposure to airborne fine particulate matter and cigarette smoke: shape of the exposure-response relationship Circulation 120 2009 941 948
6. K. Bibbins-Domingo, G.M. Chertow, and P.G. Coxson Projected effect of dietary salt reductions on future cardiovascular disease N Engl J Med 362 2010 590 599
7. S. Costanzo, A. Di Castelnuovo, M.B. Donati, L. Iacoviello, and G. de Gaetano Alcohol consumption and mortality in patients with cardiovascular disease: a meta-analysis J Am Coll Cardiol 55 2010 1339 1347
8. E.S. Ford, G. Zhao, and C. Li Pre-diabetes and the risk for cardiovascular disease: a systematic review of the evidence J Am Coll Cardiol 55 2010 1310 1317
9. E. Selvin, M.W. Steffes, and H. Zhu Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults N Engl J Med 362 2010 800 811
10. C.K. Chow, S. Jolly, P. Rao-Melacini, K.A. Fox, S.S. Anand, and S. Yusuf Association of diet, exercise, and smoking modification with risk of early cardiovascular events after acute coronary syndromes Circulation 121 2010 750 758
11. E.S. Ford, C. Li, G. Zhao, W.S. Pearson, and S. Capewell Trends in the prevalence of low risk factor burden for cardiovascular disease among United States adults Circulation 120 2009 1181 1188
12. S. Blankenberg, T. Zeller, and O. Saarela Contribution of 30 biomarkers to 10-year cardiovascular risk estimation in 2 population cohorts: the MONICA, risk, genetics, archiving, and monograph (MORGAM) biomarker project Circulation 121 2010 2388 2397
13. K.M. Eggers, B. Lagerqvist, P. Venge, L. Wallentin, and B. Lindahl Prognostic value of biomarkers during and after nonST-segment elevation acute coronary syndrome J Am Coll Cardiol 54 2009 357 364
14. D.A. Morrow, B.M. Scirica, and M.S. Sabatine B-type natriuretic peptide and the effect of ranolazine in patients with nonST-segment elevation acute coronary syndromes: observations from the MERLIN-TIMI 36 (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST Elevation Acute Coronary- Thrombolysis In Myocardial Infarction 36) trial J Am Coll Cardiol 55 2010 1189 1196
15. M. Bonaca, B. Scirica, and M. Sabatine Prospective evaluation of the prognostic implications of improved assay performance with a sensitive assay for cardiac troponin I J Am Coll Cardiol 55 2010 2118 2124
16. P. Venge, N. Johnston, B. Lindahl, and S. James Normal plasma levels of cardiac troponin I measured by the high-sensitivity cardiac troponin I access prototype assay and the impact on the diagnosis of myocardial ischemia J Am Coll Cardiol 54 2009 1165 1172
17. J.L. Januzzi Jr., F. Bamberg, and H. Lee High-sensitivity troponin T concentrations in acute chest pain patients evaluated with cardiac computed tomography Circulation 121 2010 1227 1234
18. T. Reichlin, W. Hochholzer, and S. Bassetti Early diagnosis of myocardial infarction with sensitive cardiac troponin assays N Engl J Med 361 2009 858 867
19. S.R. Wilson, M.S. Sabatine, E. Braunwald, S. Sloan, S.A. Murphy, and D.A. Morrow Detection of myocardial injury in patients with unstable angina using a novel nanoparticle cardiac troponin I assay: observations from the PROTECT-TIMI 30 Trial Am Heart J 158 2009 386 391
20. M.S. Sabatine, D.A. Morrow, J.A. de Lemos, P. Jarolim, and E. Braunwald Detection of acute changes in circulating troponin in the setting of transient stress test-induced myocardial ischaemia using an ultrasensitive assay: results from TIMI 35 Eur Heart J 30 2009 162 169
21. T. Kempf, J.M. Sinning, and A. Quint Growth-differentiation factor-15 for risk stratification in patients with stable and unstable coronary heart disease: results from the AtheroGene study Circ Cardiovasc Genet 2 2009 286 292
22. K.M. Eggers, T. Kempf, and B. Lagerqvist Growth-differentiation factor-15 for long-term risk prediction in patients stabilized after an episode of nonST-segment elevation acute coronary syndrome Circ Cardiovasc Genet 3 2010 88 96
23. T. Reichlin, W. Hochholzer, and C. Stelzig Incremental value of copeptin for rapid rule out of acute myocardial infarction J Am Coll Cardiol 54 2009 60 68
24. A.M. Jansson, P. Aukrust, and T. Ueland Soluble CXCL16 predicts long-term mortality in acute coronary syndromes Circulation 119 2009 3181 3188
25. T. Kilic, G. Oner, and E. Ural Comparison of the long-term prognostic value of cystatin C to other indicators of renal function, markers of inflammation and systolic dysfunction among patients with acute coronary syndrome Atherosclerosis 207 2009 552 558
26. A.E. Fraley, G.G. Schwartz, and A.G. Olsson Relationship of oxidized phospholipids and biomarkers of oxidized low-density lipoprotein with cardiovascular risk factors, inflammatory biomarkers, and effect of statin therapy in patients with acute coronary syndromes: results from the MIRACL (Myocardial Ischemia Reduction With Aggressive Cholesterol Lowering) trial J Am Coll Cardiol 53 2009 2186 2196
27. I. Buysschaert, K.F. Carruthers, and D.R. Dunbar A variant at chromosome 9p21 is associated with recurrent myocardial infarction and cardiac death after acute coronary syndrome: the GRACE Genetics Study Eur Heart J 31 2010 1132 1141
28. H. Cardinal, J.M. Brophy, and P. Bogaty Usefulness of soluble fas levels for improving diagnostic accuracy and prognosis for acute coronary syndromes Am J Cardiol 105 2010 797 803
29. K.M. Eggers, P.W. Armstrong, and R.M. Califf ST2 and mortality in nonST-segment elevation acute coronary syndrome Am Heart J 159 2010 788 794
30. D.A. Morrow, and E. Braunwald Future of biomarkers in acute coronary syndromes: moving toward a multimarker strategy Circulation 108 2003 250 252
31. U. Wilbert-Lampen, T. Nickel, and D. Leistner Modified serum profiles of inflammatory and vasoconstrictive factors in patients with emotional stress-induced acute coronary syndrome during World Cup Soccer 2006 J Am Coll Cardiol 55 2010 637 642
32. T.S. Polonsky, R.L. McClelland, and N.W. Jorgensen Coronary artery calcium score and risk classification for coronary heart disease prediction JAMA 303 2010 1610 1616
33. S. Motoyama, M. Sarai, and H. Harigaya Computed tomographic angiography characteristics of atherosclerotic plaques subsequently resulting in acute coronary syndrome J Am Coll Cardiol 54 2009 49 57
34. J.C. Tardif, P.L. L'Allier, and R. Ibrahim Treatment with 5-lipoxygenase inhibitor VIA-2291 (Atreleuton) in patients with recent acute coronary syndrome Circ Cardiovasc Imaging 3 2010 298 307
35. A. Thompson, P. Gao, and L. Orfei Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies Lancet 375 2010 1536 1544
36. A. Tanaka, T. Imanishi, and H. Kitabata Lipid-rich plaque and myocardial perfusion after successful stenting in patients with nonST-segment elevation acute coronary syndrome: an optical coherence tomography study Eur Heart J 30 2009 1348 1355
37. S. Seneviratne, Q.A. Truong, and F. Bamberg Incremental diagnostic value of regional left ventricular function over coronary assessment by cardiac computed tomography for the detection of acute coronary syndrome in patients with acute chest pain: from the ROMICAT trial Circ Cardiovasc Imaging 3 2010 375 383
38. L. Drouet, C. Bal dit Sollier, and J. Martin Adding intravenous unfractionated heparin to standard enoxaparin causes excessive anticoagulation not detected by activated clotting time: results of the STACK-on to ENOXaparin (STACKENOX) study Am Heart J 158 2009 177 184
39. J.A. Anderson, J. Hirsh, and S. Yusuf Comparison of the anticoagulant intensities of fondaparinux and enoxaparin in the Organization to Assess Strategies in Acute Ischemic Syndromes (OASIS)-5 trial J Thromb Haemost 8 2010 243 249
40. S.S. Jolly, D.P. Faxon, and K.A. Fox Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes treated with glycoprotein IIb/IIIa inhibitors or thienopyridines: results from the OASIS 5 (Fifth Organization to Assess Strategies in Ischemic Syndromes) trial J Am Coll Cardiol 54 2009 468 476
41. J. Silvain, F. Beygui, and A. Ankri Enoxaparin anticoagulation monitoring in the catheterization laboratory using a new bedside test J Am Coll Cardiol 55 2010 617 625
42. K. Goto, A.J. Lansky, and M. Fahy Predictors of outcomes in medically treated patients with acute coronary syndromes after angiographic triage: an acute catheterization and urgent intervention triage strategy (ACUITY) substudy Circulation 121 2010 853 862
43. R. Mehran, E. Nikolsky, and A.J. Lansky Impact of chronic kidney disease on early (30-day) and late (1-year) outcomes of patients with acute coronary syndromes treated with alternative antithrombotic treatment strategies: an ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) substudy J Am Coll Cardiol Intv 2 2009 748 757
44. S. Schulz, J. Mehilli, and G. Ndrepepa Bivalirudin vs. unfractionated heparin during percutaneous coronary interventions in patients with stable and unstable angina pectoris: 1-year results of the ISAR-REACT 3 trial Eur Heart J 31 2010 582 587
45. M.S. Sabatine, E.M. Antman, and P. Widimsky Otamixaban for the treatment of patients with nonST-elevation acute coronary syndromes (SEPIA-ACS1 TIMI 42): A randomised, double-blind, active-controlled, phase 2 trial Lancet 374 2009 787 795
46. ClinicalTrials.gov An efficacy and safety study for rivaroxaban in patients with acute coronary syndromes http://www.clinicaltrials.gov/ct2/show/ NCT00809965 Accessed November 1, 2010
47. I. Hagedorn, S. Schmidbauer, and I. Pleines Factor XIIa inhibitor recombinant human albumin infestin-4 abolishes occlusive arterial thrombus formation without affecting bleeding Circulation 121 2010 1510 1517
48. S.V. Rao, C. Melloni, and S. Myles-Dimauro Evaluation of a new heparin agent in percutaneous coronary intervention: results of the phase 2 evaluation of M118 IN pErcutaNeous Coronary intErvention (EMINENCE) Trial Circulation 121 2010 1713 1721
49. J.W. Eikelboom, and J.I. Weitz New anticoagulants Circulation 121 2010 1523 1532
50. F.G. Kushner, M. Hand, and S.C. Smith Jr. 2009 focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines J Am Coll Cardiol 54 2009 2205 2241
51. P.A. Gurbel, K.P. Bliden, and K. Butler Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study Circulation 120 2009 2577 2585
52. P.A. Gurbel, K.P. Bliden, and K. Butler Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study Circulation 121 2010 1188 1199
53. L. Wallentin, R.C. Becker, and A. Budaj Ticagrelor versus clopidogrel in patients with acute coronary syndromes N Engl J Med 361 2009 1045 1057
54. C.P. Cannon, R.A. Harrington, and S. James Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study Lancet 375 2010 283 293
55. U.S. Food and Drug Administration Plavix (clopidogrel): reduced effectiveness in patients who are poor metabolizers of the drug http://www.fda.gov/Safety/MedWatch/SafetyInformation/ SafetyAlertsforHumanMedicalProducts/ucm204256.htm Accessed October 31, 2010
56. A.R. Shuldiner, J.R. O'Connell, and K.P. Bliden Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy JAMA 302 2009 849 857
57. P. Gladding, H. White, and J. Voss Pharmacogenetic testing for clopidogrel using the rapid INFINITI analyzer: a dose-escalation study J Am Coll Cardiol Intv 2 2009 1095 1101
58. T. Gremmel, S. Steiner, D. Seidinger, R. Koppensteiner, S. Panzer, and C.W. Kopp Adenosine diphosphate-inducible platelet reactivity shows a pronounced age dependency in the initial phase of antiplatelet therapy with clopidogrel J Thromb Haemost 8 2010 37 42
59. E. Cecchi, R. Marcucci, and R. Paniccia Effect of blood hematocrit and erythrocyte deformability on adenosine 5'-diphosphate platelet reactivity in patients with acute coronary syndromes on dual antiplatelet therapy Am J Cardiol 104 2009 764 768
60. C. Combescure, P. Fontana, N. Mallouk CLOpidogrel and Vascular ISchemic Events Meta-analysis Study Group Clinical implications of clopidogrel non-response in cardiovascular patients: a systematic review and meta-analysis J Thromb Haemost 8 2010 923 933
61. W. Hochholzer, D. Trenk, and M.F. Fromm Impact of cytochrome P450 2C19 loss-of-function polymorphism and of major demographic characteristics on residual platelet function after loading and maintenance treatment with clopidogrel in patients undergoing elective coronary stent placement J Am Coll Cardiol 55 2010 2427 2434
62. T. Cuisset, C. Frere, and J. Quilici Predictive values of post-treatment adenosine diphosphate-induced aggregation and vasodilator-stimulated phosphoprotein index for stent thrombosis after acute coronary syndrome in clopidogrel-treated patients Am J Cardiol 104 2009 1078 1082
63. T. Geisler, C. Zurn, and R. Simonenko Early but not late stent thrombosis is influenced by residual platelet aggregation in patients undergoing coronary interventions Eur Heart J 31 2010 59 66
64. N.B. Norgard, K.D. Mathews, and G.C. Wall Drug-drug interaction between clopidogrel and the proton pump inhibitors Ann Pharmacother 43 2009 1266 1274
65. C.S. Zuern, T. Geisler, N. Lutilsky, S. Winter, M. Schwab, and M. Gawaz Effect of comedication with proton pump inhibitors (PPIs) on post-interventional residual platelet aggregation in patients undergoing coronary stenting treated by dual antiplatelet therapy Thromb Res 125 2010 e51 e54
66. J.A. Rassen, N.K. Choudhry, J. Avorn, and S. Schneeweiss Cardiovascular outcomes and mortality in patients using clopidogrel with proton pump inhibitors after percutaneous coronary intervention or acute coronary syndrome Circulation 120 2009 2322 2329
67. W.A. Ray, K.T. Murray, and M.R. Griffin Outcomes with concurrent use of clopidogrel and proton-pump inhibitors: a cohort study Ann Intern Med 152 2010 337 345
68. C.S. Kwok, and Y.K. Loke Meta-analysis: effects of proton pump inhibitors on cardiovascular events and mortality in patients receiving clopidogrel Aliment Pharmacol Ther 31 2010 810 823
69. D.L. Bhatt, B.L. Cryer, C.F. Contant COGENT Investigators Clopidogrel with or without omeprazole in coronary artery disease N Engl J Med 363 2010 1909 1917
70. T. Cuisset, C. Frere, and J. Quilici Comparison of omeprazole and pantoprazole influence on a high 150-mg clopidogrel maintenance dose the PACA (Proton Pump Inhibitors And Clopidogrel Association) prospective randomized study J Am Coll Cardiol 54 2009 1149 1153
71. T. Furuta, T. Iwaki, and K. Umemura [13C]pantoprazole breath test as a predictor of the anti-platelet function of clopidogrel Eur J Clin Pharmacol 66 2010 457 463
72. P.M. Ho, T.T. Tsai, and T.Y. Wang Adverse events after stopping clopidogrel in post-acute coronary syndrome patients: insights from a large integrated healthcare delivery system Circ Cardiovasc Qual Outcomes 3 2010 303 308
73. S.J. Park, D.W. Park, and Y.H. Kim Duration of dual antiplatelet therapy after implantation of drug-eluting stents N Engl J Med 362 2010 1374 1382
74. S.R. Mehta, J.P. Bassand, and S. Chrolavicius Dose comparisons of clopidogrel and aspirin in acute coronary syndromes N Engl J Med 363 2010 930 942
75. A.D. Michelson, A.L. Frelinger III, and E. Braunwald Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial Eur Heart J 30 2009 1753 1763
76. D.A. Morrow, S.D. Wiviott, and H.D. White Effect of the novel thienopyridine prasugrel compared with clopidogrel on spontaneous and procedural myocardial infarction in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction 38: an application of the classification system from the universal definition of myocardial infarction Circulation 119 2009 2758 2764
77. M. O'Donoghue, E.M. Antman, and E. Braunwald The efficacy and safety of prasugrel with and without a glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) analysis J Am Coll Cardiol 54 2009 678 685
78. E.M. Mahoney, K. Wang, and S.V. Arnold Cost-effectiveness of prasugrel versus clopidogrel in patients with acute coronary syndromes and planned percutaneous coronary intervention: results from the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with Prasugrel-Thrombolysis in Myocardial Infarction TRITON-TIMI 38 Circulation 121 2010 71 79
79. A.J. Deibele, L.K. Jennings, J.E. Tcheng, C. Neva, A.D. Earhart, and C.M. Gibson Intracoronary Eptifibatide bolus administration during percutaneous coronary revascularization for acute coronary syndromes with evaluation of platelet glycoprotein IIb/IIIa receptor occupancy and platelet function: the intracoronary Eptifibatide (ICE) trial Circulation 121 2010 784 791
80. D.L. Bhatt, A.M. Lincoff, and C.M. Gibson Intravenous platelet blockade with cangrelor during PCI N Engl J Med 361 2009 2330 2341
81. R.A. Harrington, G.W. Stone, and S. McNulty Platelet inhibition with cangrelor in patients undergoing PCI N Engl J Med 361 2009 2318 2329
82. C.M. Gibson, Y.B. Pride, and J.L. Buros Timing and duration of myocardial ischemia on Holter monitoring following percutaneous coronary intervention and their association with clinical outcomes (a PROTECT-TIMI 30 Substudy Analysis) Am J Cardiol 104 2009 36 40
83. TRA (*)CER Executive and Steering Committees The Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRA (*)CER) trial: study design and rationale Am Heart J 158 2009 327 334.e4
84. D.A. Morrow, B.M. Scirica, and K.A. Fox Evaluation of a novel antiplatelet agent for secondary prevention in patients with a history of atherosclerotic disease: design and rationale for the Thrombin-Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2° P)-TIMI 50 trial Am Heart J 158 2009 335 341.e3
85. M.U. Zafar, B. Ibanez, and B.G. Choi A new oral antiplatelet agent with potent antithrombotic properties: comparison of DZ-697b with clopidogrelin a randomised phase I study Thromb Haemost 103 2010 205 212
86. I. Ben-Dor, R. Torguson, and M. Scheinowitz Incidence, correlates, and clinical impact of nuisance bleeding after antiplatelet therapy for patients with drug-eluting stents Am Heart J 159 2010 871 875
87. H.D. White, P.E. Aylward, and R. Gallo Hematomas of at least 5 cm and outcomes in patients undergoing elective percutaneous coronary intervention: insights from the SafeTy and Efficacy of Enoxaparin in PCI patients, an internationaL randomized Evaluation (STEEPLE) trial Am Heart J 159 2010 110 116
88. J.P. Bassand, R. Afzal, and J. Eikelboom Relationship between baseline haemoglobin and major bleeding complications in acute coronary syndromes Eur Heart J 31 2010 50 58
89. S.V. Rao, J. Eikelboom, and P.G. Steg Standardized reporting of bleeding complications for clinical investigations in acute coronary syndromes: a proposal from the academic bleeding consensus (ABC) multidisciplinary working group Am Heart J 158 2009 881 886.e1
90. R. Mehran, S.J. Pocock, and G.W. Stone Associations of major bleeding and myocardial infarction with the incidence and timing of mortality in patients presenting with nonST-elevation acute coronary syndromes: a risk model from the ACUITY trial Eur Heart J 30 2009 1457 1466
91. S.J. Pocock, R. Mehran, and T.C. Clayton Prognostic modeling of individual patient risk and mortality impact of ischemic and hemorrhagic complications: assessment from the Acute Catheterization and Urgent Intervention Triage Strategy trial Circulation 121 2010 43 51
92. R. Sorensen, M.L. Hansen, and S.Z. Abildstrom Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data Lancet 374 2009 1967 1974
93. G.Y. Lip, K. Huber, and F. Andreotti Consensus Document of the European Society of Cardiology Working Group on Thrombosis Antithrombotic management of atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing coronary stenting: executive summary Eur Heart J 31 2010 1311 1318
94. S.S. Jolly, S. Amlani, M. Hamon, S. Yusuf, and S.R. Mehta Radial versus femoral access for coronary angiography or intervention and the impact on major bleeding and ischemic events: a systematic review and meta-analysis of randomized trials Am Heart J 157 2009 132 140
95. T.A. Sanborn, R. Ebrahimi, and S.V. Manoukian Impact of femoral vascular closure devices and antithrombotic therapy on access site bleeding in acute coronary syndromes: The Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) trial Circ Cardiovasc Interv 3 2010 57 62
96. D.R. Putney, N.S. Kleiman, R.E. Fromm Jr., and J.M. Buergler Impact of computerized dosing on eptifibatide-associated bleeding and mortality Am Heart J 158 2009 1018 1023
97. E. Nikolsky, G.W. Stone, and A.J. Kirtane Gastrointestinal bleeding in patients with acute coronary syndromes: incidence, predictors, and clinical implications: analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial J Am Coll Cardiol 54 2009 1293 1302
98. J.J. Sung, J.Y. Lau, and J.Y. Ching Continuation of low-dose aspirin therapy in peptic ulcer bleeding: a randomized trial Ann Intern Med 152 2010 1 9
99. M. Singh, N. Mehta, U.K. Murthy, V. Kaul, A. Arif, and N. Newman Postpolypectomy bleeding in patients undergoing colonoscopy on uninterrupted clopidogrel therapy Gastrointest Endosc 71 2010 998 1005
100. R.C. Becker, J. Scheiman, and H.L. Dauerman Management of platelet-directed pharmacotherapy in patients with atherosclerotic coronary artery disease undergoing elective endoscopic gastrointestinal procedures J Am Coll Cardiol 54 2009 2261 2276
101. S.R. Dixon, C.L. Grines, and W.W. O'Neill The year in interventional cardiology J Am Coll Cardiol 55 2010 2272 2286
102. K.A. Fox, T.C. Clayton, and P. Damman Long term outcome of a routine versus selective invasive strategy in patients with nonST-segment elevation acute coronary syndrome: A meta-analysis of individual patient data J Am Coll Cardiol 55 2010 2435 2445
103. E. Swahn, J. Alfredsson, and R. Afzal Early invasive compared with a selective invasive strategy in women with nonST-elevation acute coronary syndromes: a substudy of the OASIS 5 trial and a meta-analysis of previous randomized trials Eur Heart J 2009 Feb 7 [E-pub ahead of print]; doi:10.1093/eurheartj/ehp009.
104. J.L. Mega, J.S. Hochman, and B.M. Scirica Clinical features and outcomes of women with unstable ischemic heart disease: observations from metabolic efficiency with ranolazine for less ischemia in nonST-elevation acute coronary syndromes-thrombolysis in myocardial infarction 36 (MERLIN-TIMI 36) Circulation 121 2010 1809 1817
105. J.S. Berger, L. Elliott, and D. Gallup Sex differences in mortality following acute coronary syndromes JAMA 302 2009 874 882
106. B. Grenne, C. Eek, and B. Sjoli Changes of myocardial function in patients with nonST-elevation acute coronary syndrome awaiting coronary angiography Am J Cardiol 105 2010 1212 1218
107. P. Sorajja, B.J. Gersh, and D.A. Cox Impact of delay to angioplasty in patients with acute coronary syndromes undergoing invasive management: analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial J Am Coll Cardiol 55 2010 1416 1424
108. G. Montalescot, G. Cayla, and J.P. Collet Immediate vs delayed intervention for acute coronary syndromes: a randomized clinical trial JAMA 302 2009 947 954
109. M.W. Deyell, W.A. Ghali, D.B. Ross, J. Zhang, and B.R. Hemmelgarn Timing of nonemergent coronary artery bypass grafting and mortality after non-ST elevation acute coronary syndrome Am Heart J 159 2010 490 496
110. M.G. Cohen, S.J. Filby, and M.T. Roe The paradoxical use of cardiac catheterization in patients with nonST-elevation acute coronary syndromes: lessons from the Can Rapid Stratification of Unstable Angina Patients Suppress Adverse Outcomes With Early Implementation of the ACC /AHA Guidelines (CRUSADE) Quality Improvement Initiative Am Heart J 158 2009 263 270
111. S. Jedrzkiewicz, S.G. Goodman, and R.T. Yan Temporal trends in the use of invasive cardiac procedures for non-ST segment elevation acute coronary syndromes according to initial risk stratification Can J Cardiol 25 2009 e370 e376
112. A.J. Bagnall, S.G. Goodman, and K.A. Fox Influence of age on use of cardiac catheterization and associated outcomes in patients with nonST-elevation acute coronary syndromes Am J Cardiol 103 2009 1530 1536
113. K. Szummer, P. Lundman, and S.H. Jacobson Influence of renal function on the effects of early revascularization in nonST-elevation myocardial infarction: data from the Swedish Web-System for Enhancement and Development of Evidence-Based Care in Heart Disease Evaluated According to Recommended Therapies (SWEDEHEART) Circulation 120 2009 851 858
114. R. Wessely, T. Koppara, and C. Bradaric Choice of contrast medium in patients with impaired renal function undergoing percutaneous coronary intervention Circ Cardiovasc Interv 2 2009 430 437
115. M. Brueck, D. Bandorski, W. Kramer, M. Wieczorek, R. Holtgen, and H. Tillmanns A randomized comparison of transradial versus transfemoral approach for coronary angiography and angioplasty J Am Coll Cardiol Intv 2 2009 1047 1054
116. T. Hiro, T. Kimura, and T. Morimoto Effect of intensive statin therapy on regression of coronary atherosclerosis in patients with acute coronary syndrome: a multicenter randomized trial evaluated by volumetric intravascular ultrasound using pitavastatin versus atorvastatin (JAPAN-ACS [Japan assessment of pitavastatin and atorvastatin in acute coronary syndrome] study) J Am Coll Cardiol 54 2009 293 302
117. J. Rodes-Cabau, J.C. Tardif, and M. Cossette Acute effects of statin therapy on coronary atherosclerosis following an acute coronary syndrome Am J Cardiol 104 2009 750 757
118. C.R. Rahilly-Tierney, E.V. Lawler, R.E. Scranton, and J.M. Gaziano Cardiovascular benefit of magnitude of low-density lipoprotein cholesterol reduction: a comparison of subgroups by age Circulation 120 2009 1491 1497
119. G. Di Sciascio, G. Patti, V. Pasceri, A. Gaspardone, G. Colonna, and A. Montinaro Efficacy of atorvastatin reload in patients on chronic statin therapy undergoing percutaneous coronary intervention: results of the ARMYDA-RECAPTURE (Atorvastatin for Reduction of Myocardial Damage During Angioplasty) Randomized Trial J Am Coll Cardiol 54 2009 558 565
120. K.H. Yun, S.K. Oh, S.J. Rhee, N.J. Yoo, N. Kim, and J. Jeong 12-month follow-up results of high dose rosuvastatin loading before percutaneous coronary intervention in patients with acute coronary syndrome Int J Cardiol 2010 May 14 [E-pub ahead of print]; doi: 101016/j.ijcard.2010.04.052
121. C.M. Gibson, Y.B. Pride, C.P. Hochberg, S. Sloan, M.S. Sabatine, and C.P. Cannon Effect of intensive statin therapy on clinical outcomes among patients undergoing percutaneous coronary intervention for acute coronary syndrome PCI-PROVE IT: A PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) Substudy J Am Coll Cardiol 54 2009 2290 2295
122. R.M. Califf, Y. Lokhnygina, and C.P. Cannon An update on the IMProved reduction of outcomes: Vytorin Efficacy International Trial (IMPROVE-IT) design Am Heart J 159 2010 705 709
123. S.P. Zhao, D.Q. Peng, B.L. Yu, and Y. Huo Rationale and design of China intensive lipid lowering with statins in acute coronary syndrome: the CHILLAS study Am Heart J 158 2009 509 512.e1
124. S.D. Wiviott, S. Mohanavelu, J.S. Raichlen, V.A. Cain, S.E. Nissen, and P. Libby Safety and efficacy of achieving very low low-density lipoprotein cholesterol levels with rosuvastatin 40 mg daily (from the ASTEROID Study) Am J Cardiol 104 2009 29 35
125. L.C. Correia, M.S. Rocha, and J.P. Esteves HDL-cholesterol level provides additional prognosis in acute coronary syndromes Int J Cardiol 136 2009 307 314
126. G.G. Schwartz, A.G. Olsson, and C.M. Ballantyne Rationale and design of the dal-OUTCOMES trial: efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome Am Heart J 158 2009 896 901.e3
127. C.P. Cannon, H.M. Dansky, and M. Davidson Design of the DEFINE trial: determining the EFficacy and tolerability of CETP INhibition with AnacEtrapib Am Heart J 158 2009 513 519.e3
128. P.J. Barter, M. Caulfield, and M. Eriksson Effects of torcetrapib in patients at high risk for coronary events N Engl J Med 357 2007 2109 2122
129. E.D. Peterson, E.R. Delong, and F.A. Masoudi ACCF/AHA 2010 Position Statement on Composite Measures for Healthcare Performance Assessment: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Performance Measures (Writing Committee to Develop a Position Statement on Composite Measures) J Am Coll Cardiol 55 2010 1755 1766
130. E.A. Amsterdam, E.D. Peterson, and F.S. Ou Comparative trends in guidelines adherence among patients with nonST-segment elevation acute coronary syndromes treated with invasive versus conservative management strategies: results from the CRUSADE quality improvement initiative Am Heart J 158 2009 748 754.e1
131. Y. Xian, W. Pan, and E.D. Peterson Are quality improvements associated with the Get With the Guidelines-Coronary Artery Disease (GWTG-CAD) program sustained over time? A longitudinal comparison of GWTG-CAD hospitals versus nonGWTG-CAD hospitals Am Heart J 159 2010 207 214
132. D.D. Waters, C. Brotons, and C.W. Chiang Lipid treatment assessment project 2: a multinational survey to evaluate the proportion of patients achieving low-density lipoprotein cholesterol goals Circulation 120 2009 28 34
133. T.M. Brown, A.F. Hernandez, and V. Bittner Predictors of cardiac rehabilitation referral in coronary artery disease patients: findings from the American Heart Association's Get With The Guidelines Program J Am Coll Cardiol 54 2009 515 521
134. P.M. Ho, T.T. Tsai, and T.M. Maddox Delays in filling clopidogrel prescription after hospital discharge and adverse outcomes after drug-eluting stent implantation: implications for transitions of care Circ Cardiovasc Qual Outcomes 3 2010 261 266
135. A.D. Michaels, S.A. Spinler, and B. Leeper Medication errors in acute cardiovascular and stroke patients: a scientific statement from the American Heart Association Circulation 121 2010 1664 1682
136. M. Herman, J. Donovan, and M. Tran Use of beta-blockers and effects on heart rate and blood pressure post-acute coronary syndromes: are we on target? Am Heart J 158 2009 378 385
137. C. Melloni, K.P. Alexander, and F.S. Ou Predictors of early discontinuation of evidence-based medicine after acute coronary syndrome Am J Cardiol 104 2009 175 181
138. S. Baroletti, and H. Dell'Orfano Medication adherence in cardiovascular disease Circulation 121 2010 1455 1458
139. P.M. Ho, C.L. Bryson, and J.S. Rumsfeld Medication adherence: its importance in cardiovascular outcomes Circulation 119 2009 3028 3035
140. L. Grimaldi-Bensouda, L. Abenhaim, and L. Michaud Clinical features and risk factors for upper gastrointestinal bleeding in children: a case-crossover study Eur J Clin Pharmacol 66 2010 831 837
141. J.L. Schnipper, C.L. Roumie, and C. Cawthon Rationale and design of the Pharmacist Intervention for Low Literacy in Cardiovascular Disease (PILL-CVD) study Circ Cardiovasc Qual Outcomes 3 2010 212 219
142. D.M. Lloyd-Jones, Y. Hong, and D. Labarthe Defining and setting national goals for cardiovascular health promotion and disease reduction: the American Heart Association's strategic Impact Goal through 2020 and beyond Circulation 121 2010 586 613